Docoh
Loading...

SYN Synthetic Biologics

Document and Entity Information

Document and Entity Information - shares3 Months Ended
Mar. 31, 2021May 04, 2021
Document and Entity Information
Document Type10-Q
Document Period End DateMar. 31,
2021
Entity Registrant NameSynthetic Biologics, Inc.
Title of 12(b) SecurityCommon Stock
Security Exchange NameNYSE
Entity Current Reporting StatusYes
Entity Interactive Data CurrentYes
Entity Filer CategoryNon-accelerated Filer
Entity Small Businesstrue
Entity Emerging Growth Companyfalse
Entity Shell Companyfalse
Entity Common Stock, Shares Outstanding132,042,538
Entity Central Index Key0000894158
Current Fiscal Year End Date--12-31
Document Fiscal Year Focus2021
Document Fiscal Period FocusQ1
Amendment Flagfalse
Trading SymbolSYN

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in ThousandsMar. 31, 2021Dec. 31, 2020
Current Assets
Cash and cash equivalents $ 76,887 $ 6,227
Prepaid expenses and other current assets1,749 1,707
Total Current Assets78,636 7,934
Property and equipment, net156 174
Right of use asset239 279
Deposits and other assets23 23
Total Assets79,054 8,410
Current Liabilities:
Accounts payable621 886
Accrued expenses854 925
Accrued employee benefits350 868
Operating lease liability297 287
Total Current Liabilities2,122 2,966
Lease liability - long term108 186
Total Liabilities2,230 3,152
Commitments and Contingencies
Series A convertible preferred stock, $0.001 par value; 10,000,000 shares authorized; 0 and 120,000 issued and outstanding as of March 31, 2021 and December 31, 2020, respectively0 12,798
Stockholders' Equity (Deficit):
Series B convertible preferred stock, $1,000 par value; 10,000,000 shares authorized, 0 issued and outstanding and 3,973 issued and outstanding as of March 31, 2021 and December 31, 2020, respectively0 2,477
Common stock, $0.001 par value; 200,000,000 shares authorized, 132,044,866 issued and 132,042,538 outstanding at March 31, 2021 and 29,252,253 issued and 29,249,925 outstanding at December 31, 2020132 29
Additional paid-in capital339,019 240,821
Accumulated deficit(259,553)(248,094)
Total Synthetic Biologics, Inc. and Subsidiaries Equity (Deficit)79,598 (4,767)
Non-controlling interest(2,774)(2,773)
Total Stockholders' Equity (Deficit)76,824 (7,540)
Total Liabilities and Stockholders' Equity (Deficit) $ 79,054 $ 8,410

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / sharesMar. 31, 2021Dec. 31, 2020
Condensed Consolidated Balance Sheets
Temporary Equity, Par or Stated Value Per Share $ 0.001 $ 0.001
Temporary Equity, Shares Authorized10,000,000 10,000,000
Temporary Equity, Shares Issued0 120,000
Temporary Equity, Shares Outstanding0 120,000
Preferred Stock, Par or Stated Value Per Share $ 1,000 $ 1,000
Preferred Stock, Shares Authorized10,000,000 10,000,000
Preferred Stock, Shares Issued0 3,973
Preferred Stock, Shares Outstanding0 3,973
Common stock, par value (in dollars per share) $ 0.001 $ 0.001
Common stock, Shares Authorized200,000,000 200,000,000
Common stock, Shares Issued132,044,866 29,252,253
Common stock, Shares Outstanding132,042,538 29,249,925

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($)3 Months Ended
Mar. 31, 2021Mar. 31, 2020
Operating Costs and Expenses:
General and administrative $ 1,419,000 $ 1,393,000
Research and development1,118,000 1,635,000
Total Operating Costs and Expenses2,537,000 3,028,000
Loss from Operations(2,537,000)(3,028,000)
Other Income :
Interest income0 38,000
Total Other Income0 38,000
Net Loss(2,537,000)(2,990,000)
Net Loss Attributable to Non-controlling Interest(1,000)(26,000)
Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries(2,536,000)(2,964,000)
Effect of Series A Preferred Stock Price adjustment(7,402,000)0
Net Loss Attributable to Common Stockholders $ (11,459,000) $ (3,430,000)
Net Loss Per Share - Basic and Dilutive $ (0.13) $ (0.20)
Weighted average number of shares outstanding during the period - Basic and Dilutive90,807,693 17,093,920
Series A Preferred Stock [Member]
Other Income :
Preferred Stock Dividends, Income Statement Impact $ (24,000) $ (62,000)
Effect of Series A Preferred Stock Price adjustment7,402,000
Series B Preferred Stock [Member]
Other Income :
Net Loss Attributable to Non-controlling Interest0 0
Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries0 0
Preferred Stock Dividends, Income Statement Impact $ (1,497,000) $ (404,000)

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders Equity (Deficit) - USD ($)Common Stock [Member]Additional Paid-in Capital [Member]Accumulated Deficit [Member]Noncontrolling Interest [Member]Series B Preferred Stock [Member]Total
Balance at Dec. 31, 2019 $ 17,000 $ 232,580,000 $ (235,537,000) $ (2,878,000) $ 4,761,000 $ (1,057,000)
Balance (in shares) at Dec. 31, 201916,806,430 7,638
Stock-based compensation $ 0 83,000 0 0 $ 0 83,000
Series A Preferred Stock Dividends0 0 (62,000)0 0 (62,000)
Issuance of SYN Biomics Stock $ 0 0 0 26,000 $ 0 26,000
Conversion of Series B Preferred Stock to Common (in shares)933,045 (1,073)
Conversion of Series B Preferred Stock to Common $ 1,000 1,072,000 (404,000)0 $ (669,000)0
Net loss0 0 (2,964,000)0 (2,964,000)
Non-controlling interest0 0 (26,000)0 (26,000)
Balance at Mar. 31, 2020 $ 18,000 233,735,000 (238,967,000)(2,878,000) $ 4,092,000 (4,000,000)
Balance (in shares) at Mar. 31, 202017,739,475 6,565
Balance at Dec. 31, 2020 $ 29,000 240,821,000 (248,094,000)(2,773,000) $ 2,477,000 (7,540,000)
Balance (in shares) at Dec. 31, 202029,249,925 3,973
Stock-based compensation $ 0 101,000 0 0 $ 0 101,000
Stock issued under "at-the-market" offering $ 79,000 65,881,000 0 0 0 65,960,000
Stock issued under "at-the-market" offering (in shares)78,685,315
Warrants Exercised $ 12,000 8,030,000 0 0 0 8,042,000
Warrants Exercised (In shares)11,655,747
Series A Preferred Stock Dividends $ 0 0 (24,000)0 (24,000)
Effect of Series A Preferred Stock price adjustment $ 0 7,402,000 (7,402,000)0 $ 0 0
Conversion of Series B Preferred Stock to Common (in shares)3,454,783 (3,973)
Conversion of Series B Preferred Stock to Common $ 3,000 3,971,000 (1,497,000)0 $ (2,477,000)0
Conversion of Series A Preferred Stock to Common $ 9,000 12,813,000 0 0 0 12,822,000
Conversion of Series A Preferred Stock to Common (in shares)8,996,768
Net loss $ 0 0 (2,536,000)0 (2,536,000)
Non-controlling interest0 0 (1,000)0 (1,000)
Balance at Mar. 31, 2021 $ 132,000 $ 339,019,000 $ (259,553,000) $ (2,774,000) $ 0 $ 76,824,000
Balance (in shares) at Mar. 31, 2021132,042,538

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands3 Months Ended
Mar. 31, 2021Mar. 31, 2020
Cash Flows From Operating Activities:
Net loss $ (2,537) $ (2,990)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation101 83
Subsidiary stock issuances to vendor0 26
Depreciation33 58
Changes in operating assets and liabilities:
Prepaid expenses and other current assets(42)297
Right of use asset39 33
Accounts payable(265)(1,068)
Accrued expenses(71)(714)
Accrued employee benefits(518)(626)
Lease liability(68)(59)
Net Cash Used In Operating Activities(3,328)(4,960)
Cash Flows From Investing Activities:
Purchases of property and equipment(14)0
Net Cash Used In Investing Activities(14)0
Cash Flows From Financing Activities:
Proceeds from "at the market" stock issuance65,960 0
Proceeds from issuance of common stock for warrant exercises8,042 0
Net Cash Provided By Financing Activities74,002 0
Net increase (decrease) in cash and cash equivalents70,660 (4,960)
Cash and cash equivalents at the beginning of this period6,227 15,045
Cash and cash equivalents at the end of this period76,887 10,085
NONCASH FINANCING ACTIVITIES:
Effect of Series A Preferred Stock price adjustment7,402 0
Conversion of Series B Preferred Stock2,477 669
Deemed dividends for accretion of Series B Preferred Stock discount1,497 404
In-kind dividends paid in preferred stock $ 23 $ 62

Organization, Nature of Operati

Organization, Nature of Operations and Basis of Presentation3 Months Ended
Mar. 31, 2021
Organization, Nature of Operations and Basis of Presentation
Organization, Nature of Operations and Basis of Presentation1. Organization, Nature of Operations and Basis of Presentation
Description of Business
Synthetic Biologics, Inc. (the “Company” or “Synthetic Biologics”) is a diversified clinical-stage company developing therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need. The Company’s lead clinical development candidates are: (1) SYN-004 (ribaxamase) which is designed to degrade certain commonly used intravenous (IV) beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent (a) microbiome damage, (b) Clostridioides difficile infection (CDI), (c) overgrowth of pathogenic organisms, (d) the emergence of antimicrobial resistance (AMR) and (e) acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients, and (2) SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under Current Good Manufacturing Practice (cGMP) conditions and intended to treat both local GI and systemic diseases.
Basis of Presentation
The accompanying condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, they do not include all of the information and notes required by Accounting Principles Generally Accepted in the United States of America (“U.S. GAAP”) for complete financial statements. The accompanying condensed consolidated financial statements include all adjustments, comprised of normal recurring adjustments, considered necessary by management to fairly state the Company’s results of operations, financial position and cash flows. The operating results for the interim periods are not necessarily indicative of results that may be expected for any other interim period or for the full year. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s 2020 Form 10‑K. The interim results for the three months ended March 31, 2021 are not necessarily indicative of results for the full year.
The condensed consolidated financial statements are prepared in conformity with U.S. GAAP, which requires the use of estimates, judgments and assumptions that affect the amounts of assets and liabilities at the reporting date and the amounts of revenue and expenses in the periods presented. The Company believes that the accounting estimates employed are appropriate and the resulting balances are reasonable; however, due to the inherent uncertainties in making estimates, actual results may differ from the original estimates, requiring adjustments to these balances in future periods.
Recent Accounting Pronouncements and Developments
In August 2020, the Financial Accounting Standards Board ("FASB”) issued Accounting Standards Update ("ASU")2020-06 Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (subtopic 815-40) : Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity . This ASU amends the guidance on convertible instruments and the derivatives scope exception for contracts in an entity’s own equity and improves and amends the related earnings per share guidance for both Subtopics. The ASU will be effective for annual reporting periods after December 15, 2023 and interim periods within those annual periods and early adoption is permitted in annual reporting periods ending after December 15, 2020. The Company is currently assessing the impact of ASU 2020-06 on its consolidated financial statements.
Impairment of Long-Lived Assets
Long-lived assets include property, equipment and right-of-use assets. In accordance with ASC 360, Property, Plant and Equipment (“ASC 360”), management reviews the Company’s long-lived assets for impairment annually or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be fully recoverable. The Company determines the extent to which an asset may be impaired based upon its expectation of the asset’s future usability as well as whether there is reasonable assurance that the future cash flows associated with the asset will be in excess of its carrying amount. If the total of the expected undiscounted future cash flows is less than the carrying amount of the asset, a loss is recognized for the difference between the fair value and the carrying value of the asset. The Company identified COVID-19 as a triggering event and performed a qualitative assessment of the fair value of its long-lived assets. The results from this analysis determined that it is still more likely than not that the fair value of its long-lived assets remain higher than the carrying value of these assets. As a result, no impairment charges were recorded during the three months ended March 31, 2021 and 2020.

Fair Value of Financial Instrum

Fair Value of Financial Instruments3 Months Ended
Mar. 31, 2021
Fair Value of Financial Instruments
Fair Value of Financial Instruments2. Fair Value of Financial Instruments
Accounting Standards Codification (“ASC”) Topic 820, Fair Value Measurement , defines fair value as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is determined based upon assumptions that market participants would use in pricing an asset or liability. Fair value measurements are rated on a three-tier hierarchy as follows:
·
Level 1 inputs: Quoted prices (unadjusted) for identical assets or liabilities in active markets;
·
Level 2 inputs: Inputs, other than quoted prices, included in Level 1 that are observable either directly or indirectly; and
·
Level 3 inputs: Unobservable inputs for which there is little or no market data, which require the reporting entity to develop its own assumptions.
In many cases, a valuation technique used to measure fair value includes inputs from multiple levels of the fair value hierarchy described above. The lowest level of significant input determines the placement of the entire fair value measurement in the hierarchy.
The carrying amounts of the Company’s short-term financial instruments, including cash and cash equivalents, other current assets, accounts payable and accrued liabilities approximate fair value due to the relatively short period to maturity for these instruments.
The Company uses Monte Carlo simulations to estimate the fair value of its stock warrants. In using this model, the fair value is determined by applying Level 3 inputs for which there is little or no observable market data, requiring the Company to develop its own assumptions. The assumptions used in calculating the estimated fair value of the warrants represent the Company's best estimates; however, these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change and different assumptions are used, the warrant liability and the change in estimated fair value could be materially different.

Selected Balance Sheet Informat

Selected Balance Sheet Information3 Months Ended
Mar. 31, 2021
Selected Balance Sheet Information
Selected Balance Sheet Information3. Selected Balance Sheet Information
Prepaid expenses and other current assets (in thousands)
March 31,
December 31,
2021
2020
Prepaid clinical research organizations
$
1,138
$
470
Prepaid insurances
442
639
Prepaid consulting, subscriptions and other expenses
169
90
Stock sales receivable

469
Prepaid manufacturing expenses

39
Total
$
1,749
$
1,707
Prepaid clinical research organizations (CROs) expense is classified as a current asset. The Company makes payments to the CROs based on agreed upon terms that include payments in advance of study services.
Property and equipment, net (in thousands)
March 31,
December 31,
2021
2020
Computers and office equipment
$
828
$
813
Leasehold improvements
439
439
Software
11
11
1,278
1,263
Less: accumulated depreciation and amortization
(1,122)
(1,089)
Total
$
156
$
174
Accrued expenses (in thousands)
March 31,
December 31,
2021
2020
Accrued clinical consulting services
$
669
$
700
Accrued vendor payments
137
225
Accrued manufacturing costs
46

Other accrued expenses
2

Total
$
854
$
925
Accrued employee benefits (in thousands)
March 31,
December 31,
2021
2020
Accrued bonus expense
$
180
$
724
Accrued vacation expense
170
144
Total
$
350
$
868

Stock-Based Compensation

Stock-Based Compensation3 Months Ended
Mar. 31, 2021
Stock-Based Compensation
Stock-Based Compensation4 . Stock-Based Compensation
Stock Incentive Plans
On March 20, 2007, the Company’s Board of Directors approved the 2007 Stock Incentive Plan (the “2007 Stock Plan”) for the issuance of up to 71,429 shares of common stock to be granted through incentive stock options, nonqualified stock options, stock appreciation rights, dividend equivalent rights, restricted stock, restricted stock units and other stock-based awards to officers, other employees, directors and consultants of the Company and its subsidiaries. This plan was approved by the stockholders on November 2, 2007. The exercise price of stock options under the 2007 Stock Plan was determined by the compensation committee of the Board of Directors and could be equal to or greater than the fair market value of the Company’s common stock on the date the option is granted. The total number of shares of stock with respect to which stock options and stock appreciation rights may be granted to any one employee of the Company or a subsidiary during any one-year period under the 2007 stock plan shall not exceed 7,143. Options become exercisable over various periods from the date of grant and generally expire ten years after the grant date. As of March 31, 2021, there were 5,145 options issued and outstanding under the 2007 Stock Plan.
On November 2, 2010, the Board of Directors and stockholders adopted the 2010 Stock Incentive Plan (“2010 Stock Plan”) for the issuance of up to 85,714 shares of common stock to be granted through incentive stock options, nonqualified stock options, stock appreciation rights, dividend equivalent rights, restricted stock, restricted stock units and other stock-based awards to officers, other employees, directors and consultants of the Company and its subsidiaries. On October 22, 2013, the stockholders approved and adopted an amendment to the Company’s 2010 Stock Plan to increase the number of shares of Company’s common stock reserved for issuance under the Plan from 85,714 to 171,429; on May 15, 2015, increased the number of shares from 171,429 to 228,572; on August 25, 2016, increased the number of shares from 228,572 to 400,000; on September 7, 2017, increased the number of shares from 400,000 to 500,000; on September 24, 2018 increased the number of shares from 500,000 to 1,000,000; and on September 5, 2019, increased the number of shares from 1,000,000 to 4,000,000. The exercise price of stock options under the 2010 Stock Plan is determined by the compensation committee of the Board of Directors and may be equal to or greater than the fair market value of the Company’s common stock on the date the option is granted. Options become exercisable over various periods from the date of grant, and expire between five and ten years after the grant date. As of March 31, 2021, there were 2,452,273 options issued and outstanding under the 2010 Stock Plan.
On September 17, 2020, the stockholders approved and adopted the 2020 Stock Incentive Plan (“2020 Stock Plan”) for the issuance of up to 4,000,000 shares of Common Stock to be granted through incentive stock options, nonqualified stock options, stock appreciation rights, dividend equivalent rights, restricted stock, restricted stock units and other stock-based awards to officers, other employees, directors and consultants of the Company and its subsidiaries. As of March 31, 2021, there were 1,540,000 options issued and outstanding under the 2010 Stock Plan.
In the event of an employee’s termination, the Company will cease to recognize compensation expense for that employee. Stock forfeitures are recognized as incurred. There is no deferred compensation recorded upon initial grant date. Instead, the fair value of the stock-based payment is recognized over the stated vesting period.
The Company has applied fair value accounting for all stock-based payment awards since inception. The fair value of each option granted is estimated on the date of grant using the Black-Scholes option pricing model. There were no options granted during the three months ended March 31, 2021 and 2020.
Expected dividends — The Company has never declared or paid dividends on its common stock and has no plans to do so in the foreseeable future.
Expected volatility —Volatility is a measure of the amount by which a financial variable such as a share price has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period. The expected volatility assumption is derived from the historical volatility of the Company’s common stock over a period approximately equal to the expected term.
Risk-free interest rate —The assumed risk free rate used is a zero coupon U.S. Treasury security with a maturity that approximates the expected term of the option.
Expected life of the option —The period of time that the options granted are expected to remain unexercised. Options granted during the year have a maximum term of seven years. The Company estimates the expected life of the option term based on the weighted average life between the dates that options become fully vested and the maximum life of options granted.
The Company records stock-based compensation based upon the stated vesting provisions in the related agreements. The vesting provisions for these agreements have various terms as follows:
·
immediate vesting,
·
in full on the one-year anniversary date of the grant date,
·
half vesting immediately and the remaining over three years,
·
quarterly over three years,
·
annually over three years,
·
one-third immediate vesting and the remaining annually over two years,
·
one-half immediate vesting and the remaining over nine months,
·
one-quarter immediate vesting and the remaining over three years,
·
one-quarter immediate vesting and the remaining over 33 months,
·
monthly over one year, and
·
monthly over three years.
A summary of stock option activity for the three months ended March 31, 2021 and the year ended December 31, 2020 is as follows:
Weighted
Weighted Average
Aggregate
Average Exercise
Remaining
Intrinsic
Options
Price
Contractual Life
Value
Balance - December 31, 2019
2,502,012
$
3.62
6.51 years
$
153,353
Granted
1,540,000
0.42
Exercised


Expired
(14,944)
17.57
Forfeited
(29,650)
0.55
Balance - December 31, 2020
3,997,418
2.35
6.09 years

Granted


Exercised


Expired


Forfeited


Balance - March 31, 2021 - outstanding
3,997,418
$
5.53 years
$
856,227
Balance - March 31, 2021 - exercisable
1,645,161
$
4.52 years
$
268,034
Grant date fair value of options granted – three months ended March 31, 2021
$

Weighted average grant date fair value – three months ended March 31, 2021
$

Grant date fair value of options granted – year ended December 31, 2020
$
412,000
Weighted average grant date fair value – year ended December 31, 2020
$
0.27
Stock-based compensation expense included in general and administrative expenses and research and development expenses relating to stock options issued to employees for the three months ended March 31, 2021 and 2020 was $49,000 and $55,000, respectively. Stock-based compensation expense included in general and administrative expenses and research and development expenses relating to stock options issued to consultants for the three months ended March 31, 2021 and 2010 were $52,000 and $28,000, respectively.
As of March 31, 2021, total unrecognized stock-based compensation expense related to stock options was $585,000, which is expected to be expensed through February 2023.
The FASB’s guidance for stock-based payments requires cash flows from excess tax benefits to be classified as a part of cash flows from operating activities. Excess tax benefits are realized tax benefits from tax deductions for exercised options in excess of the deferred tax asset attributable to stock compensation costs for such options. The Company did not record any excess tax benefits during the three months ended March 31, 2021 and 2020.

Stock Warrants

Stock Warrants3 Months Ended
Mar. 31, 2021
Stock Warrants
Stock Warrants5 . Stock Warrants
On October 15, 2018, the Company closed its underwritten public offering pursuant to which it received gross proceeds of approximately $18.6 million before deducting underwriting discounts, commissions and other offering expenses payable by the Company and sold an aggregate of (i) 2,520,000 Class A Units (the “Class A Units”), with each Class A Unit consisting of one share of the Common Stock, and one five-year warrant to purchase one share of Common Stock at an initial exercise price of $1.38 per share, which subsequently was reduced to $0.69 per share (each a “Warrant” and collectively, the “Warrants”), with each Class A Unit to be offered to the public at a public offering price of $1.15, and (ii) 15,723 Class B Units (the “Class B Units”, and together with the Class A Units, the “Units”), with each Class B Unit offered to the public at a public offering price of $1,000 per Class B Unit and consisting of one share of the Company’s Series B Convertible Preferred Stock (the “Series B Preferred Stock”), with a stated value of $1,000 and convertible into shares of Common Stock at the stated value divided by a conversion price of $1.15 per share, with all shares of Series B Preferred Stock convertible into an aggregate of 13,672,173 shares of Common Stock, and issued with an aggregate of 13,672,173 Warrants. On November 16, 2020, the exercise price of the Warrants was reduced from $1.38 per Warrant per full share of the Company’s common stock, $0.001 par value per share (the “Common Stock”), to $0.69 per Warrant per full share of Common Stock in accordance with the anti-dilution terms of the Warrant. The reduction was the result of the issuance of shares of Common Stock by the Company through its “at the market offering” facility. The effect of the change in the exercise price of the warrants as a result of the triggering of the down round protection clause in the Warrants was recorded as a deemed dividend of $880,000, which reduces the income available to common stockholders. In addition, pursuant to the underwriting agreement that the Company had entered into with A.G.P./Alliance Global Partners (the “Underwriters”), as representative of the underwriters, the Company granted the Underwriters a 45 day option (the “Over-allotment Option”) to purchase up to an additional 2,428,825 shares of Common Stock and/or additional Warrants to purchase an additional 2,428,825 shares of Common Stock. The Underwriters partially exercised the Over-allotment Option by electing to purchase from the Company additional Warrants to purchase 1,807,826 shares of Common Stock.
The Warrants are immediately exercisable at a price of $1.38 ($0.69 effective November 16, 2020) per share of Common Stock (which was 120% of the public offering price of the Class A Units) and expire on October 15, 2023. If, at the time of exercise, there is no effective registration statement registering, or no current prospectus available for, the issuance of the shares of Common Stock to the holder, then the Warrants may only be exercised through a cashless exercise. No fractional shares of Common Stock will be issued in connection with the exercise of a Warrant. In lieu of fractional shares, the holder will receive an amount in cash equal to the fractional amount multiplied by the fair market value of any such fractional shares. The Company has concluded that the Warrants are required to be equity classified. The Warrants were valued on the date of grant using Monte Carlo simulations. During the three months ended March 31, 2021, 11,655,747 warrants were exercised for cash proceeds of $8.0 million.
On November 18, 2016, the Company completed a public offering of 714,286 shares of common stock in combination with accompanying warrants to purchase an aggregate of 1,428,571 shares of the common stock. The stock and warrants were sold in combination, with two warrants for each share of common stock sold, a Series A warrant and a Series B warrant, each representing the right to purchase one share of common stock. The purchase price for each share of common stock and accompanying warrants was $35.00. The shares of common stock were immediately separable from the warrants and were issued separately. The initial per share exercise price of the Series A warrants was $50.05 and the per share exercise price of the Series B warrants was $60.20, each subject to adjustment as specified in the warrant agreements. The Series A and Series B warrants could be exercised at any time on or after the date of issuance. The Series A warrants were exercisable until the four-year anniversary of the issuance date. The Series B warrants expired December 31, 2017 and none were exercised prior to expiration. The Series A warrants expired November 18, 2020 and none were exercised prior to expiration. The warrants included a provision, that if the Company were to enter into a certain transaction, as defined in the agreement, the warrants would be purchased from the holder for cash. Accordingly, the Company recorded the warrants as a liability at their estimated fair value on the issuance date of $15.7 million and changes in estimated fair value will be recorded as non-cash income or expense in the Company’s Statement of Operations at each subsequent period. At December 31, 2019, the fair value of the warrant liability was $100. The warrants were valued on the date of grant and on each remeasurement period.
A summary of all warrant activity for the Company for the quarter ended March 31, 2021 and the year ended December 31, 2020 is as follows:
Number of
Weighted Average
Warrants
Exercise Price
Balance at December 31, 2019
18,714,999
3.24
Granted


Exercised


Forfeited
(714,286)
50.05
Balance at December 31, 2020
18,000,713
$
0.69
Granted


Exercised
11,655,747
0.69
Forfeited


Balance at March 31, 2021
6,344,966
$
0.69
On December 26, 2017, the Company entered into a consulting agreement for advisory services for a period of six months. As compensation for such services, the consultant was paid an upfront payment, was paid a monthly fee and on January 24, 2018 was issued a warrant exercisable for 714 shares of the Company’s common stock on the date of issue. The warrant is equity classified and the fair value of the warrant approximated $9,000 and was measured using the Black-Scholes option pricing model.
A summary of all outstanding and exercisable common stock warrants as of March 31, 2021 is as follows:
Weighted Average
Warrants
Warrants
Remaining
Exercise Price
Outstanding
Exercisable
Contractual Life
$
0.69
6,344,252
6,344,252
2.53 years
18.20
714
714
1.74 years
$
0.69
6,344,966
6,344,966
2.53 years

Net Loss per Share

Net Loss per Share3 Months Ended
Mar. 31, 2021
Net Loss per Share
Net Loss per Share6 . Net Loss per Share
Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding. Diluted net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding including the effect of common share equivalents. Diluted net loss per share assumes the issuance of potential dilutive common shares outstanding for the period and adjusts for any changes in income and the repurchase of common shares that would have occurred from the assumed issuance, unless such effect is anti-dilutive. Net loss attributable to common stockholders for the three months ended March 31, 2020 excludes net loss attributable to non-controlling interest of $0.1 million and includes the accretion of the Series B preferred discount of $1.5 million as a result of converted shares and Series A preferred stock accrued dividends of Tagg million and the deemed dividend of $7.4 million resulting from the effect of the Series A preferred stock price adjustment during the first quarter of 2021. Net loss attributable to common stockholders for the three months ended March 31, 2020 excludes net loss attributable to non-controlling interest of $0.1 million, includes the accretion of Series B preferred discount of $0.4 million on converted shares and $0.1 million of Series A accrued dividends. There were no shares of common stock underlying Series B Preferred shares convertible to common stock that were excluded from the computations of net loss per common share for the three months ended March 31, 2021 since all remaining Series B preferred stock were converted to common stock. The number of shares of common stock underlying Series B Preferred shares convertible to common stock that were excluded from the computations of net loss per common share for the three months ended March 31, 2020 were 5,708,696. The number of options and warrants for the purchase of common stock that were excluded from the computations of net loss per common share and for the three months ended March 31, 2021 were 3,997,418 and 6,344,966, respectively and for the three months ended March 31, 2020 were 2,502,012 and 18,714,999, respectively, because their effect is anti-dilutive.

Non-controlling Interest

Non-controlling Interest3 Months Ended
Mar. 31, 2021
Non-controlling Interest
Non-controlling Interest7 . Non-controlling Interest
The Company’s non-controlling interest is accounted for under ASC 810, Consolidation (“ASC 810”), and represents the minority shareholder’s ownership interest related to the Company’s subsidiary, Synthetic Biomics, Inc. (“SYN Biomics”). In accordance with ASC 810, the Company reports its non-controlling interest in subsidiaries as a separate component of equity in the Consolidated Balance Sheets and reports both net loss attributable to the non-controlling interest and net loss attributable to the Company’s common stockholders on the face of the Consolidated Statements of Operations. On September 5, 2018, the Company entered into an agreement with CSMC for an investigator-sponsored Phase 2b clinical study of SYN-010 to be co-funded by the Company and CSMC (the “Study”). The Study was to provide further evaluation of the efficacy and safety of SYN-010, the Company’s modified-release reformulation of lovastatin lactone, which was exclusively licensed to the Company by CSMC. SYN-010 is designed to reduce methane production by certain microorganisms ( M. smithii ) in the gut to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C). After the 2018 transaction with CSMC, the Company’s equity interest in SYN Biomics is 83% and the non-controlling stockholder’s interest is 17%. As of March 31, 2021 and 2020, the accumulated net loss attributable to the non-controlling interest is $2.8 million and $2.9 million, respectively.
In consideration of the support provided by CSMC for the Study, the Company paid $328,000 to support the Study and the Company entered into a Stock Purchase Agreement with CSMC pursuant to which the Company, upon the approval of the Study protocol by the Institutional Review Board (IRB) : (i) issued to CSMC fifty thousand (50,000) shares of common stock of the Company; and (ii) transferred to CSMC an additional two million four hundred twenty thousand (2,420,000) shares of common stock of its subsidiary SYN Biomics, Inc. (“Synbiomics”) owned by the Company, such that after such issuance CSMC owns an aggregate of seven million four hundred eighty thousand (7,480,000) shares of common stock of SYN Biomics, representing seventeen percent (17%) of the issued and outstanding shares of SYN Biomics’ common stock. The services rendered are recorded to research and development expense in proportion with the progress of the study and based overall on the fair value of the shares ($285,000) as determined at the date of IRB approval. During the three months ended March 31, 2020, research and development expense recorded related to this transaction approximated $67,000. There was no expense recorded related to this transaction during the three months ended March 31, 2021.
The Agreement also provided CSMC with a right, commencing on the six month anniversary of issuance of the stock under certain circumstances in the event that the shares of stock of SYN Biomics are not then freely tradeable, and subject to NYSE American, LLC approval, to exchange its SYN Biomics shares for unregistered shares of the Company’s common stock, with the rate of exchange based upon the relative contribution of the valuation of SYN Biomics to the public market valuation of the Company at the time of each exchange. The Stock Purchase Agreement also provides for tag-along rights in the event of the sale by the Company of its shares of SYN Biomics.
On September 30, 2020, CSMC MAST formally agreed to discontinue the ongoing Phase 2b investigator-sponsored clinical study of SYN-010 following the results of a planned interim futility analysis. Although it was concluded that SYN-010 was well tolerated, SYN-010 was unlikely to meet its primary endpoint by the time enrollment is completed.
On November 9, 2020, the Company and its subsidiary, Synthetic Biomics, Inc. and CSMC mutually agreed to terminate the exclusive license agreement dated December 5, 2013 and all amendments thereto and the clinical trial agreement relating to SYN-010. The determination to terminate the SYN-010 license agreement was agreed following the completion of a planned interim futility analysis of the Phase 2b investigator-sponsored clinical trial of SYN-010. On September 30, 2020, CSMC (the Company’s SYN-010 clinical development partner) informed the Company that it discontinued the ongoing Phase 2b investigator-sponsored clinical study of SYN-010 IBS-C patients.

Common and Preferred Stock

Common and Preferred Stock3 Months Ended
Mar. 31, 2021
Common and Preferred Stock
Common and Preferred Stock8 . Common and Preferred Stock
Series B Preferred Stock
On October 15, 2018, the Company closed its underwritten public offering pursuant to which it received gross proceeds of approximately $18.6 million before deducting underwriting discounts, commissions and other offering expenses payable by the Company and sold an aggregate of (i) 2,520,000 Class A Units , with each Class A Unit offered to the public at a public offering price of $1.15, and (ii) 15,723 Class B Units, with each Class B Unit offered to the public at a public offering price of $1,000 per Class B Unit and consisting of one share of the Company’s Series B Preferred Stock, with a stated value of $1,000 and convertible into shares of Common Stock at the stated value divided by a conversion price of $1.15 per share, with all shares of Series B Preferred Stock convertible into an aggregate of 13,672,173 shares of Common Stock, and issued with an aggregate of 13,672,173 October 2018 Warrants. Since the above units are equity instruments, the proceeds were allocated on a relative fair value basis which created the Series B Preferred Stock discount.
In addition, pursuant to the Underwriting Agreement that the Company entered into with the Underwriters on October 10, 2018, the Company granted the Underwriters a 45 day option (the “Over-allotment Option”) to purchase up to an additional 2,428,825 shares of Common Stock and/or additional warrants to purchase an additional 2,428,825 shares of Common Stock. Each Warrant is exercisable for one share of common stock. The Underwriters partially exercised the Over-allotment Option by electing to purchase from the Company additional Warrants to purchase 1,807,826 shares of Common Stock.
The Units were offered by the Company pursuant to a registration statement on Form S‑1 (File No. 333‑227400), as amended, filed with the SEC, which was declared effective by the SEC on October 10, 2018.
The conversion price of the Series B Preferred Stock and exercise price of the October 2018 Warrants is subject to appropriate adjustment in the event of recapitalization events, stock dividends, stock splits, stock combinations, reclassifications, reorganizations or similar events affecting the Common Stock. The exercise price of the Warrants is subject to adjustment in the event of certain dilutive issuances.
On November 16, 2020, the exercise price of the Warrants was reduced from $1.38 per Warrant per full share of common stock to $0.69 per Warrant per full share of common stock. The reduction was the result of the issuance of shares of Common Stock by the Company through its “at the market offering” facility. The effect of the change in the exercise price of the warrants as a result of the triggering of the down round protection clause in the Warrants was recorded as a deemed dividend in accumulated deficit of $880,000, which reduces the income available to common stockholders for the year ended December 31, 2020.
The October 2018 Warrants are immediately exercisable at a price of $1.38 ($0.69 effective November 16, 2020) per share of common stock (which was 120% of the public offering price of the Class A Units) and will expire on October 15, 2023. If, at the time of exercise, there is no effective registration statement registering, or no current prospectus available for, the issuance of the shares of common stock to the holder, then the October 2018 warrants may only be exercised through a cashless exercise. No fractional shares of common stock will be issued in connection with the exercise of any October 2018 warrants. In lieu of fractional shares, the holder will receive an amount in cash equal to the fractional amount multiplied by the fair market value of any such fractional shares.
Since the effective conversion price of the Series B Preferred Stock is less than the fair value of the underlying common stock at the date of issuance, there is a beneficial conversion feature (“BCF”) at the issuance date. Because the Series B Preferred Stock has no stated maturity or redemption date and is immediately convertible at the option of the holder, the discount created by the BCF is immediately charged to accumulated deficit as a “deemed dividend” and impacts earnings per share. During the three months ended March 31, 2021 and 2020, 3,973 and 1,073, respectively, shares were converted resulting in the recognition of a deemed dividends of $1.5 million and $404,000, respectively, for the amortization of the Series B Preferred Stock discount upon conversion.
Series A Preferred Stock
On September 11, 2017, the Company entered into a share purchase agreement (the “Purchase Agreement”) with an investor (the “Investor”), pursuant to which the Company offered and sold in a private placement 120,000 shares of its Series A Convertible Preferred Stock, par value $0.001 per share (the “Series A Preferred Stock”) for an aggregate purchase price of $12 million, or $100 per share.
The Series A Preferred Stock ranks senior to the shares of the Company's common stock, and any other class or series of stock issued by the Company with respect to dividend rights, redemption rights and rights to the distribution of assets on any voluntary or involuntary liquidation, dissolution or winding up of the affairs of the Company. Holders of Series A Preferred Stock are entitled to a cumulative dividend at the rate of 2.0% per annum, payable quarterly in arrears, as set forth in the Certificate of Designation of Series A Preferred Stock classifying the Series A Preferred Stock. The Series A Preferred Stock is convertible at the option of the holders at any time into shares of common stock at an initial conversion price of $0.54 per share which was increased to $18.90 after taking into account the 2018 reverse stock split, subject to certain customary anti-dilution adjustments and was decreased to $1.50 on January 27, 2021, see below.
Any conversion of Series A Preferred Stock may be settled by the Company in shares of common stock only.
The holder’s ability to convert the Series A Preferred Stock into common stock is subject to (i) a 19.99% blocker provision to comply with NYSE American Listing Rules, (ii) if so elected by the Investor, a 4.99% blocker provision that will prohibit beneficial ownership of more than 4.99% of the outstanding shares of the Company’s common stock or voting power at any time, and (iii) applicable regulatory restrictions.
In the event of any liquidation, dissolution or winding-up of the Company, holders of the Series A Preferred Stock are entitled to a preference on liquidation equal to the greater of (i) an amount per share equal to the stated value plus any accrued and unpaid dividends on such share of Series A Preferred Stock (the “Accreted Value”), and (ii) the amount such holders would receive in such liquidation if they converted their shares of Series A Preferred Stock (based on the Accreted Value and without regard to any conversion limitation) into shares of the common stock immediately prior to any such liquidation, dissolution or winding-up (the greater of (i) and (ii), is referred to as the “Liquidation Value”).
Except as otherwise required by law, the holders of Series A Preferred Stock have no voting rights, other than customary protections against adverse amendments and issuance of pari passu or senior preferred stock. Upon certain change of control events involving the Company, prior to the filing of the amendment to the Certificate of Designation for the Series A Preferred Stock described below, the Company will be required to repurchase all of the Series A Preferred Stock at a redemption price equal to the greater of (i) the Accreted Value and (ii) the amount that would be payable upon a change of control (as defined in the Certificate of Designation) in respect of common stock issuable upon conversion of such share of Series A Preferred Stock if all outstanding shares of Series A Preferred Stock were converted into common stock immediately prior to the change of control.
On or at any time after (i) the VWAP (as defined in the Certificate of Designation) for at least 20 trading days in any 30 trading day period is greater than $70.00, subject to adjustment in the case of stock split, stock dividends or the like the Company has the right, after providing notice not less than 6 months prior to the redemption date, to redeem, in whole or in part, on a pro rata basis from all holders thereof based on the number of shares of Series A Preferred Stock then held, the outstanding Series A Preferred Stock, for cash, at a redemption price per share of Series A Preferred Stock of $7,875.00, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Series A Convertible Preferred Stock or (ii) the five year anniversary of the issue date, the Company shall have the right to redeem, in whole or in part, on a pro rata basis from all holders thereof based on the number of shares of Series A Convertible Preferred Stock then held, the outstanding Series A Preferred Stock, for cash, at a redemption price per share equal to the Liquidation Value.
The Series A Preferred Stock is classified as temporary equity due to the shares being redeemable based on contingent events outside of the Company’s control. Since the effective conversion price of the Series A Preferred Stock is less than the fair value of the underlying common stock at the date of issuance, there is a beneficial conversion feature (“BCF”) at the issuance date. Because the Series A Preferred Stock has no stated maturity or redemption date and is immediately convertible at the option of the holder, the discount created by the BCF is immediately charged to accumulated deficit as a “deemed dividend” and impacts earnings per share. During the year ended December 31, 2017, the Company recorded a discount of $6.9 million. Because the Series A Preferred Stock is not currently redeemable, the discount arising from issuance costs was allocated to temporary equity and will not be accreted until such time that redemption becomes probable. The stated dividend rate of 2% per annum is cumulative and the Company accrues the dividend on a quarterly basis (in effect accreting the dividend regardless of declaration because the dividend is cumulative). During the three months ended March 31, 2021 and 2020, the Company accrued dividends of $24,000 and $62,000, respectively. Once the dividend is declared, the Company will reclassify the declared amount from temporary equity to a dividends payable liability. When the redemption of the Series A Preferred Stock becomes probable, the temporary equity will be accreted to redemption value as a deemed dividend.
On January 27, 2021, the Company filed an amendment to the Certificate of Designation for the Series A Preferred Stock to (i) lower the stated Conversion Price through September 30, 2021 and (ii) remove their change in control put, as an inducement for the holder to fully convert its Series A Preferred Stock. The Amendment to the Certificate of Designation for its Series A Convertible Preferred Stock (the “Certificate of Amendment”) with the Secretary of State of the State of Nevada adjusted the conversion price from $18.90 per share to $1.50 per share and removed the redemption upon change of control. The Company received notice from the holder of the Series A Preferred Stock that it was increasing the Maximum Percentage as defined in the “Certificate of Designation” from 4.99% to 9.99%, such increase to be effective 61 days from the date hereof. During the three months ended March 31, 2021, all outstanding shares of Series A Convertible Preferred Stock were converted to approximately 9.0 million shares of the Company’s common stock. There are no remaining shares of the Series A Convertible Preferred stock outstanding after these conversions. During January and February 2021, the Company issued 8,996,768 shares of its common stock upon the conversion effected on such date by the holder of 120,000 shares of its Series A Convertible Preferred Stock. The fair value of the consideration issued to the holder to induce conversion is accounted for as a deemed dividend and increased net loss available to common shareholders for purposes of calculating loss per share. The Company estimated fair value of the inducement consideration of $7.4 million and as a result has recorded a corresponding deemed dividend of $7.4 million during the three months ended March 31, 2021.
B. Riley Securities Sales Agreement
On August 5, 2016, the Company entered into the B. Riley FBR Sales Agreement with FBR Capital Markets & Co. (now known as B. Riley Securities), which enables the Company to offer and sell shares of common stock from time to time through B. Riley Securities, Inc. as the Company’s sales agent. Sales of common stock under the B. Riley Securities Sales Agreement are made in sales deemed to be “at-the-market” equity offerings as defined in Rule 415 promulgated under the Securities Act. B. Riley Securities, Inc. is entitled to receive a commission rate of up to 3.0% of gross sales in connection with the sale of the Common Stock sold on the Company’s behalf. The Company did not sell any shares of common stock during the three months ended March 31, 2020 through the Riley Securities Sales Agreement.
On February 9, 2021, the Company entered into an amended and restated sales agreement with B. Riley Securities, Inc. (“B. Riley”) and A.G.P./Alliance Global Partners (“AGP”) in order to include AGP as an additional sales agent for the Company’s “at the market offering” program (the “Amended and Restated Sales Agreement”). The Sales Agreement amended and restated the At Market Issuance Sales Agreement, dated August 5, 2016, with B. Riley Securities, Inc. (formerly known as B. Riley FBR, Inc.), as amended by amendment no. 1, dated May 7, 2018, to the At Market Issuance Sales Agreement.
During the three months ended March 31, 2021, the Company sold through the At Market Issuance Sales Agreement and the Amended and Restated Sales Agreement approximately 78.7 million shares of the Company’s common stock and received net proceeds of approximately $65.0 million.

Related Party Transactions

Related Party Transactions3 Months Ended
Mar. 31, 2021
Related Party Transactions
Related Party Transactions9 . Related Party Transactions
On September 5, 2018, the Company entered into an agreement with CSMC for an investigator-sponsored Phase 2b clinical study of SYN‑010 to be co-funded by the Company and CSMC (the “Study”). The Study will provide further evaluation of the efficacy and safety of SYN‑010, the Company’s modified-release reformulation of lovastatin lactone, which is exclusively licensed to the Company by CSMC. SYN‑010 is designed to reduce methane production by certain microorganisms ( M. smithii ) in the gut to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C).
In consideration of the support provided by CSMC for the Study, the Company entered into a Stock Purchase Agreement with CSMC pursuant to which the Company: (i) issued to CSMC fifty thousand (50,000) shares of common stock of the Company; and (ii) transferred to CSMC an additional two million four hundred twenty thousand (2,420,000) shares of common stock of its subsidiary Synthetic Biomics, Inc. (“SYN Biomics”) owned by the Company, such that after such issuance CSMC owns an aggregate of seven million four hundred eighty thousand (7,480,000) shares of common stock of SYN Biomics, representing seventeen percent (17%) of the issued and outstanding shares of SYN Biomics’ common stock.
The Agreement also provided CSMC with a right, commencing on the six month anniversary of issuance of the stock under certain circumstances in the event that the shares of stock of SYN Biomics are not then freely tradeable, and subject to NYSE American, LLC approval, to exchange its SYN Biomics shares for unregistered shares of the Company’s common stock, with the rate of exchange based upon the relative contribution of the valuation of SYN Biomics to the public market valuation of the Company at the time of each exchange. The Stock Purchase Agreement also provides for tag-along rights in the event of the sale by the Company of its shares of SYN Biomics.
On September 30, 2020, CSMC MAST formally agreed to discontinue the ongoing Phase 2b investigator-sponsored clinical study of SYN-010 following the results of a planned interim futility analysis. Although it was concluded that SYN-010 was well tolerated, SYN-010 was unlikely to meet its primary endpoint by the time enrollment is completed.
On November 9, 2020, the Company and its subsidiary, Synthetic Biomics, Inc. and CSMC mutually agreed to terminate the exclusive license agreement dated December 5, 2013 and all amendments thereto and the clinical trial agreement relating to SYN-010. The determination to terminate the SYN-010 license agreement was agreed following the completion of a planned interim futility analysis of the Phase 2b investigator-sponsored clinical trial of SYN-010. On September 30, 2020, CSMC (the Company’s SYN-010 clinical development partner) informed the Company that it discontinued the ongoing Phase 2b investigator-sponsored clinical study of SYN-010 IBS-C patients.
In December 2013, through the Company’s subsidiary, Synthetic Biomics, Inc., the Company entered into a worldwide exclusive license agreement with CSMC and acquired the rights to develop products for therapeutic and prophylactic treatments of acute and chronic diseases, including the development of SYN-010 to target IBS-C. The Company licensed from CSMC a portfolio of intellectual property comprised of several U.S. and foreign patents and pending patent applications for various fields of use, including IBS-C, obesity and diabetes. An investigational team led by Mark Pimentel, M.D. at CSMC discovered that these products may reduce the production of methane gas by certain GI microorganisms. During the three months ended March 31, 2021 and 2020, the Company did not owe and did not pay CSMC for milestone payments related to
this license agreement.

Commitments and Contingencies

Commitments and Contingencies3 Months Ended
Mar. 31, 2021
Commitments and contingencies
Commitments and Contingencies10. Commitments and Contingencies
Leases
All of the Company’s existing leases as of March 31, 2021 are classified as operating leases. As of March 31, 2021, the Company has one material operating lease for facilities with a remaining term expiring in 2022. The existing lease has fair value renewal options, none of which are considered certain of being exercised or included in the minimum lease term. The discount rate used in the calculation of the lease liability was 9.9%. The rates implicit within the Company's leases are generally not determinable, therefore, the Company's incremental borrowing rate is used to determine the present value of lease payments. The determination of the Company’s incremental borrowing rate requires judgment. Because the Company currently has no outstanding debt, the incremental borrowing rate for each lease is primarily based on publicly available information for companies within the same industry and with similar credit profiles. The rate is then adjusted for the impact of collateralization, the lease term and other specific terms included in the Company’s lease arrangements. The incremental borrowing rate is determined at lease commencement, or as of January 1, 2019 for operating leases in existence upon adoption of ASC 842. The incremental borrowing rate is subsequently reassessed upon a modification to the lease arrangement. ROU assets are subsequently assessed for impairment in accordance with the Company’s accounting policy for long-lived assets. Operating lease costs are presented as part of general and administrative expenses in the condensed consolidated statements of operations, and for the three months ended March 31, 2021 and 2020 approximated $51,000 and $50,000, respectively. During the same periods, operating cash flows used for operating leases approximated $79,000 and $77,000, respectively, and right of use assets exchanged for operating lease obligations was $0. The day one non-cash addition of right of use assets due to adoption of ASC 842 was $538,000.
A maturity analysis of our operating leases as of March 31, 2021 is as follows (amounts in thousands of dollars) :
Future undiscounted cash flow for the years ending March 31:
2021
$
242
2022
192
Total
$
434
Discount factor
$
(29)
Lease liability
$
405
Amount due within 12 months
$
(297)
Lease liability – long term
$
108
Risks and Uncertainties
On January 30, 2020, the World Health Organization (“WHO”) announced a global health emergency because of a new strain of coronavirus originating in Wuhan, China (the “COVID-19” outbreak) and the risks to the international community as the virus spreads globally beyond its point of origin. In March 2020, the WHO classified the COVID-19 outbreak as a pandemic, based on the rapid increase in exposure globally.
As COVID-19 continued to spread around the globe, the Company experienced disruptions that impacted its business and clinical trials, including halting the postponement of clinical site initiation of the Phase 1b/2a clinical trial of SYN-004. The extent to which the COVID-19 pandemic impacts the Company’s business, the clinical development of SYN-004 (ribaxamase) and SYN-020, the business of the Company’s suppliers and other commercial partners, the Company’s corporate development objectives and the value of and market for the Company’s common stock, will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, such as the ultimate duration of the pandemic, travel restrictions, quarantines, social distancing and business closure requirements in the United States, Europe and other countries, and the effectiveness of actions taken globally to contain and treat the disease. The global economic slowdown, the overall disruption of global healthcare systems and the other risks and uncertainties associated with the pandemic could have a material adverse effect on the Company's business, financial condition, results of operations and growth prospects. In addition, to the extent the ongoing COVID-19 pandemic adversely affects the Company’s business and results of operations, it may also have the effect of heightening many of the other risks and uncertainties which the Company faces.

Selected Balance Sheet Inform_2

Selected Balance Sheet Information (Tables)3 Months Ended
Mar. 31, 2021
Selected Balance Sheet Information
Schedule of prepaid expenses and other current assetsPrepaid expenses and other current assets (in thousands)
March 31,
December 31,
2021
2020
Prepaid clinical research organizations
$
1,138
$
470
Prepaid insurances
442
639
Prepaid consulting, subscriptions and other expenses
169
90
Stock sales receivable

469
Prepaid manufacturing expenses

39
Total
$
1,749
$
1,707
Schedule of property, plant and equipment, netProperty and equipment, net (in thousands)
March 31,
December 31,
2021
2020
Computers and office equipment
$
828
$
813
Leasehold improvements
439
439
Software
11
11
1,278
1,263
Less: accumulated depreciation and amortization
(1,122)
(1,089)
Total
$
156
$
174
Schedule of accrued expensesAccrued expenses (in thousands)
March 31,
December 31,
2021
2020
Accrued clinical consulting services
$
669
$
700
Accrued vendor payments
137
225
Accrued manufacturing costs
46

Other accrued expenses
2

Total
$
854
$
925
Schedule of accrued employee benefitsMarch 31,
December 31,
2021
2020
Accrued clinical consulting services
$
669
$
700
Accrued vendor payments
137
225
Accrued manufacturing costs
46

Other accrued expenses
2

Total
$
854
$
925
Accrued employee benefits (in thousands)
March 31,
December 31,
2021
2020
Accrued bonus expense
$
180
$
724
Accrued vacation expense
170
144
Total
$
350
$
868

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)3 Months Ended
Mar. 31, 2021
Stock-Based Compensation
Summary of stock option activityA summary of stock option activity for the three months ended March 31, 2021 and the year ended December 31, 2020 is as follows:
Weighted
Weighted Average
Aggregate
Average Exercise
Remaining
Intrinsic
Options
Price
Contractual Life
Value
Balance - December 31, 2019
2,502,012
$
3.62
6.51 years
$
153,353
Granted
1,540,000
0.42
Exercised


Expired
(14,944)
17.57
Forfeited
(29,650)
0.55
Balance - December 31, 2020
3,997,418
2.35
6.09 years

Granted


Exercised


Expired


Forfeited


Balance - March 31, 2021 - outstanding
3,997,418
$
5.53 years
$
856,227
Balance - March 31, 2021 - exercisable
1,645,161
$
4.52 years
$
268,034
Grant date fair value of options granted – three months ended March 31, 2021
$

Weighted average grant date fair value – three months ended March 31, 2021
$

Grant date fair value of options granted – year ended December 31, 2020
$
412,000
Weighted average grant date fair value – year ended December 31, 2020
$
0.27

Stock Warrants (Tables)

Stock Warrants (Tables)3 Months Ended
Mar. 31, 2021
Stock Warrants
Summary of all warrant activityA summary of all warrant activity for the Company for the quarter ended March 31, 2021 and the year ended December 31, 2020 is as follows:
Number of
Weighted Average
Warrants
Exercise Price
Balance at December 31, 2019
18,714,999
3.24
Granted


Exercised


Forfeited
(714,286)
50.05
Balance at December 31, 2020
18,000,713
$
0.69
Granted


Exercised
11,655,747
0.69
Forfeited


Balance at March 31, 2021
6,344,966
$
0.69
Summary of all outstanding and exercisable warrantsA summary of all outstanding and exercisable common stock warrants as of March 31, 2021 is as follows:
Weighted Average
Warrants
Warrants
Remaining
Exercise Price
Outstanding
Exercisable
Contractual Life
$
0.69
6,344,252
6,344,252
2.53 years
18.20
714
714
1.74 years
$
0.69
6,344,966
6,344,966
2.53 years

Commitments and Contingencies (

Commitments and Contingencies (Tables)3 Months Ended
Mar. 31, 2021
Commitments and contingencies
Schedule of maturity analysis of operating leasesFuture undiscounted cash flow for the years ending March 31:
2021
$
242
2022
192
Total
$
434
Discount factor
$
(29)
Lease liability
$
405
Amount due within 12 months
$
(297)
Lease liability – long term
$
108

Selected Balance Sheet Inform_3

Selected Balance Sheet Information - Schedule of prepaid expenses and other current assets (Details) - USD ($) $ in ThousandsMar. 31, 2021Dec. 31, 2020
Selected Balance Sheet Information
Prepaid clinical research organizations $ 1,138 $ 470
Prepaid insurances442 639
Prepaid consulting, subscriptions and other expenses169 90
Stock sales receivable0 469
Prepaid manufacturing expenses0 39
Total $ 1,749 $ 1,707

Selected Balance Sheet Inform_4

Selected Balance Sheet Information - Schedule of property, plant and equipment, net (Details) - USD ($) $ in ThousandsMar. 31, 2021Dec. 31, 2020
Property and equipment, net
Property, Plant and Equipment, Gross, Total $ 1,278 $ 1,263
Less: accumulated depreciation and amortization(1,122)(1,089)
Total156 174
Computers and office equipment [Member]
Property and equipment, net
Property, Plant and Equipment, Gross, Total828 813
Leasehold Improvements [Member]
Property and equipment, net
Property, Plant and Equipment, Gross, Total439 439
Software [Member]
Property and equipment, net
Property, Plant and Equipment, Gross, Total $ 11 $ 11

Selected Balance Sheet Inform_5

Selected Balance Sheet Information - Schedule of accrued expenses (Details) - USD ($) $ in ThousandsMar. 31, 2021Dec. 31, 2020
Selected Balance Sheet Information
Accrued clinical consulting services $ 669 $ 700
Accrued vendor payments137 225
Accrued manufacturing costs46
Other accrued expenses2 0
Total $ 854 $ 925

Selected Balance Sheet Inform_6

Selected Balance Sheet Information - Schedule of accrued employee benefits (Details) - USD ($) $ in ThousandsMar. 31, 2021Dec. 31, 2020
Selected Balance Sheet Information
Accrued bonus expense $ 180 $ 724
Accrued vacation expense170 144
Total $ 350 $ 868

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of stock option activity (Details) - USD ($)Nov. 16, 2020Mar. 31, 2021Mar. 31, 2020Dec. 31, 2020Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options, Exercised0
Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options, Beginning Balance3,997,418 2,502,012 2,502,012
Options, Granted0 0 1,540,000
Options, Exercised0 0
Options, Expired0 (14,944)
Options, Forfeited0 (29,650)
Options, Ending Balance3,997,418 3,997,418 2,502,012
Options, Exercisable1,645,161
Weighted Average Exercise Price, Beginning Balance $ 2.35 $ 3.62 $ 3.62
Weighted Average Exercise Price, Granted0 0.42
Weighted Average Exercise Price, Exercised0 0
Weighted Average Exercise Price, Expired0 17.57
Weighted Average Exercise Price, Forfeited0 0.55
Weighted Average Exercise Price, Ending Balance2.35 $ 2.35 $ 3.62
Weighted Average Exercise Price, Exercisable $ 5.10
Weighted Average Remaining Contractual Life, Balance Outstanding5 years 6 months 11 days6 years 1 month 2 days6 years 6 months 4 days
Weighted Average Remaining Contractual Life, Exercisable4 years 6 months 7 days
Aggregate Intrinsic Value, Ending Balance $ 856,227 $ 0 $ 153,353
Aggregate Intrinsic Value, Exercisable268,034
Grant date fair value of options granted $ 0 $ 412,000
Weighted average grant date fair value $ 0 $ 0.27

Stock-Based Compensation - Stoc

Stock-Based Compensation - Stock incentive plan and other information (Details) - USD ($)Sep. 05, 2019Mar. 20, 2007Mar. 31, 2021Mar. 31, 2020Mar. 31, 2010Sep. 17, 2020Sep. 24, 2018Sep. 07, 2017Aug. 25, 2016May 15, 2015Oct. 22, 2013Nov. 02, 2010
Share-based Compensation Arrangement by Share-based Payment Award
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options $ 585,000
General and Administrative Expenses and Research and Development Expense [Member] | Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award
Allocated Share-based Compensation Expense49,000,000 $ 55,000,000
Consultant [Member] | General and Administrative Expenses and Research and Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award
Allocated Share-based Compensation Expense $ 52,000,000 $ 28,000,000
2007 Stock Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number71,429 5,145
2007 Stock Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross7,143
2010 Stock Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number1,540,000 85,714
2010 Stock Plan [Member] | Board of Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number2,452,273
2010 Stock Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross4,000,000
Common Stock, Capital Shares Reserved for Future Issuance1,000,000 500,000 400,000 228,572 171,429
2010 Stock Plan [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross1,000,000
Common Stock, Capital Shares Reserved for Future Issuance500,000 400,000 228,572 171,429 85,714
2020 Stock Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number4,000,000

Stock Warrants - Summary of all

Stock Warrants - Summary of all warrant activity (Details) - $ / shares3 Months Ended12 Months Ended
Mar. 31, 2021Dec. 31, 2020
Stock Warrants
Number of Warrants, Beginning Balance18,000,713 18,714,999
Number of Warrants, Granted0
Number of Warrants, Exercised11,655,747
Number of Warrants, Forfeited0 (714,286)
Number of Warrants, Ending Balance6,344,966 18,000,713
Weighted Average Exercise Price, Beginning Balance $ 0.69 $ 3.24
Weighted Average Exercise Price, Granted0
Weighted Average Exercise Price, Exercised0.69
Weighted Average Exercise Price, Forfeited0 50.05
Weighted Average Exercise Price, Ending Balance $ 0.69 $ 0.69

Stock Warrants - Summary of a_2

Stock Warrants - Summary of all outstanding and exercisable warrants (Details)3 Months Ended
Mar. 31, 2021$ / sharesshares
Exercise Price 0.69 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares $ 0.69
Warrants Outstanding6,344,252
Warrants Exercisable6,344,252
Weighted Average Remaining Contractual Life (in years)2 years 6 months 11 days
Exercise Price 18.20 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares $ 18.20
Warrants Outstanding714
Warrants Exercisable714
Weighted Average Remaining Contractual Life (in years)1 year 8 months 27 days
Exercise price 3.24 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares $ 0.69
Warrants Outstanding6,344,966
Warrants Exercisable6,344,966
Weighted Average Remaining Contractual Life (in years)2 years 6 months 11 days

Stock Warrants - Stock Warrants

Stock Warrants - Stock Warrants (Details) - USD ($)Nov. 16, 2020Oct. 15, 2018Oct. 15, 2018Oct. 10, 2018Nov. 18, 2016Jan. 31, 2021Oct. 31, 2018Mar. 31, 2021Mar. 31, 2020Dec. 31, 2020Nov. 15, 2020Nov. 06, 2020Nov. 05, 2020Dec. 31, 2019Dec. 26, 2017
Equity, Class of Treasury Stock
Proceeds from "at the market" stock issuance $ 18,600,000 $ 18,600,000
Stock Issued During Period, Shares, New Issues78,700,000
Exercise price per warrant $ 0.69 $ 1.38 $ 1.38 $ 1.38 $ 1.38 $ 0.69 $ 1.38
Preferred Stock, Par or Stated Value Per Share $ 0.0010 $ 1,000 $ 1,000
Effect of Warrant exercise price adjustment $ 880,000
Percentage of issue of the public offering120.00%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period0
Cash proceeds from exercise of warrants $ 8,042,000 $ 0
Warrants Not Settleable in Cash, Fair Value Disclosure $ 9,000,000
Proceeds from Issuance of Common Stock $ 65,000,000 $ 65,960,000 $ 0
Series B Preferred Stock [Member]
Equity, Class of Treasury Stock
Preferred Stock, Par or Stated Value Per Share $ 1,000 $ 1,000
Stock Issued During Period, Value, Issued for Services $ 1,000 $ 1,000
Preferred Stock Conversion Price Per Share $ 1.15 $ 1.15
Conversion of Stock, Shares Converted13,672,173 13,672,173 3,973 1,073
Class of Warrant or Right, Number of Securities Called by Warrants or Rights13,672,173 13,672,173
IPO [Member]
Equity, Class of Treasury Stock
Stock Issued During Period, Shares, New Issues714,286
Shares Issued, Price Per Share $ 35
Class of Warrant or Right, Number of Securities Called by Warrants or Rights1,428,571
Warrants Not Settleable in Cash, Fair Value Disclosure $ 15,700,000 $ 100,000,000
IPO [Member] | Series B Warrants [Member]
Equity, Class of Treasury Stock
Exercise price per warrant $ 60.20
Over-Allotment Option [Member]
Equity, Class of Treasury Stock
Stock Issued During Period, Shares, New Issues2,428,825 2,428,825
Class of Warrant or Right, Number of Securities Called by Warrants or Rights2,428,825 2,428,825
Issue of warrants to purchase common stock1,807,826
Underwritten Public Offering [Member] | October 2018 Warrants [Member]
Equity, Class of Treasury Stock
Warrant Term5 years
Series A Warrants [Member] | IPO [Member] | Series A Warrants [Member]
Equity, Class of Treasury Stock
Exercise price per warrant $ 50.05
Warrant [Member]
Equity, Class of Treasury Stock
Class of Warrant or Right, Number of Securities Called by Warrants or Rights11,655,747
Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Warrants Exercisable Number714
Warrant [Member] | Series B Preferred Stock [Member]
Equity, Class of Treasury Stock
Conversion of Stock, Shares Converted13,672,173

Net Loss per Share - Additional

Net Loss per Share - Additional Information (Details) - USD ($)3 Months Ended
Mar. 31, 2021Mar. 31, 2020Dec. 31, 2017
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Net Loss Attributable to Non-controlling Interest $ (1,000) $ (26,000)
Series A Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Accretion of Preferred Stock Deemed Dividend7,400,000
Accretion of preferred discount $ 6,900,000
preferred stock accrued dividends24,000 62,000
Series B Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Net Loss Attributable to Non-controlling Interest0 0
Accretion of preferred discount1,500,000 404,000
Accretion of preferred discount1,500,000 400,000
preferred stock accrued dividends $ 1,497,000 $ 404,000
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount5,708,696
Equity Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount3,997,418 2,502,012
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount6,344,966 18,714,999

Non-controlling Interest (Detai

Non-controlling Interest (Details) - USD ($)Sep. 05, 2018Mar. 31, 2021Mar. 31, 2020Dec. 31, 2020
Noncontrolling Interest
Related Party Transaction, Expenses from Transactions with Related Party $ 328,000
Research and Development Expense $ 1,118,000 $ 1,635,000
Net Income (Loss) Attributable to Noncontrolling Interest $ (1,000)(26,000)
SYN Biomics [Member]
Noncontrolling Interest
Equity interest by parent83.00%
Related Party Transaction, Expenses from Transactions with Related Party $ 0
Research and Development Expense67,000
Accumulated net loss attributable to the non-controlling interest $ 2,800,000 $ 2,900,000
Cedarssinai Medical Center [Member]
Noncontrolling Interest
Number Of Common Stock To Be Issued50,000
Fair Value Of Shares Issued $ 285,000
Cedarssinai Medical Center [Member] | SYN Biomics [Member]
Noncontrolling Interest
Additional Number Of Common Stock To Be Issued2,420,000
Number Of Common Stock To Be Held By Related Party7,480,000
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners17.00%

Common and Preferred Stock (Det

Common and Preferred Stock (Details)Jan. 27, 2021$ / sharesNov. 16, 2020$ / sharessharesOct. 15, 2018USD ($)$ / sharessharesOct. 15, 2018USD ($)$ / sharessharesOct. 10, 2018sharesSep. 11, 2017USD ($)D$ / sharessharesJan. 31, 2021USD ($)sharesOct. 31, 2018$ / sharesMar. 31, 2021USD ($)$ / sharessharesMar. 31, 2020USD ($)sharesDec. 31, 2020USD ($)$ / sharessharesFeb. 28, 2021sharesJan. 26, 2021Nov. 15, 2020$ / sharesNov. 06, 2020$ / sharesNov. 05, 2020$ / sharesDec. 31, 2017USD ($)Aug. 05, 2016
Proceeds from Issuance or Sale of Equity | $ $ 18,600,000 $ 18,600,000
Stock Issued During Period, Shares, New Issues | shares78,700,000
Preferred Stock, Par or Stated Value Per Share | $ / shares $ 0.0010 $ 1,000 $ 1,000
Exercise price per warrant | $ / shares $ 0.69 $ 1.38 $ 1.38 $ 1.38 $ 1.38 $ 0.69 $ 1.38
Effect of Warrant exercise price adjustment | $ $ 880,000
Percentage of issue of the public offering120.00%
Common stock issued upon conversion | shares8,996,768
Preferred Stock, Shares Outstanding | shares0 3,973
Proceeds from Issuance of Common Stock | $ $ 65,000,000 $ 65,960,000 $ 0
Over-Allotment Option [Member]
Stock Issued During Period, Shares, New Issues | shares2,428,825 2,428,825
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares2,428,825 2,428,825
Issue of warrants to purchase common stock | shares1,807,826
Fbr Capital Markets Co [Member]
Brokerage Commission percentage3.00%
Series A Preferred Stock [Member]
Preferred Stock Conversion Price Per Share | $ / shares $ 18.90 $ 0.54
Accretion of preferred discount | $ $ 6,900,000
Preferred Stock, Dividend Rate, Percentage2.00%
Preferred Stock, Convertible, Conversion Price, Increase | $ / shares18.90
Preferred Stock, Convertible, Conversion Price, Decrease | $ / shares $ 1.50
Convertible Preferred Stock, Terms of Conversion(i) a 19.99% blocker provision to comply with NYSE American Listing Rules, (ii) if so elected by the Investor, a 4.99% blocker provision that will prohibit beneficial ownership of more than 4.99% of the outstanding shares of the Company's common stock or voting power at any time, and (iii) applicable regulatory restrictions.
Debt Instrument, Convertible, Threshold Trading Days | D20
Debt Instrument, Convertible, Threshold Consecutive Trading Days | D30
Dividends Payable, Amount Per Share | $ / shares $ 70
Adjustments to Additional Paid in Capital, Stock Split | $ $ 7,875
preferred stock accrued dividends | $ $ 24,000 $ 62,000
Maximum percentage9.99%4.99%
Common stock issued upon conversion | shares9,000,000
Preferred Stock, Shares Outstanding | shares120,000
Accretion of Preferred Stock Deemed Dividend | $ $ 7,400,000
Series A Preferred Stock [Member] | Private Placement [Member]
Stock Issued During Period, Shares, New Issues | shares120,000
Preferred Stock, Par or Stated Value Per Share | $ / shares $ 0.001
Proceeds from Issuance of Convertible Preferred Stock | $ $ 12,000,000
Sale of Stock, Consideration Received Per Transaction | $ $ 100
Series B Preferred Stock [Member]
Stock Issued During Period, Value, Issued for Services | $ $ 1,000 $ 1,000
Preferred Stock, Par or Stated Value Per Share | $ / shares $ 1,000 $ 1,000
Preferred Stock Conversion Price Per Share | $ / shares $ 1.15 $ 1.15
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares13,672,173 13,672,173
Conversion of Stock, Shares Converted | shares13,672,173 13,672,173 3,973 1,073
Accretion of preferred discount | $ $ 1,500,000 $ 404,000
preferred stock accrued dividends | $ $ 1,497,000 $ 404,000
Common Class A [Member]
Stock Issued During Period, Shares, New Issues | shares2,520,000 2,520,000
Shares Issued, Price Per Share | $ / shares $ 1.15 $ 1.15
Exercise price per warrant | $ / shares $ 1.38 $ 1.38
Percentage of issue of the public offering120.00%
Common Class B [Member]
Stock Issued During Period, Shares, New Issues | shares15,723 15,723
Preferred Stock, Par or Stated Value Per Share | $ / shares $ 1,000 $ 1,000
Preferred Stock Conversion Price Per Share | $ / shares $ 1.15 $ 1.15

Related Party Transactions (Det

Related Party Transactions (Details)Sep. 05, 2018shares
Synthetic Biomics Inc [Member]
Related Party Transaction
Additional Number Of Common Stock To Be Issued2,420,000
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners17.00%
Cedarssinai Medical Center [Member]
Related Party Transaction
Number Of Common Stock To Be Issued50,000
Cedarssinai Medical Center [Member] | Synthetic Biomics Inc [Member]
Related Party Transaction
Additional Number Of Common Stock To Be Issued2,420,000
Number Of Common Stock To Be Held By Related Party7,480,000
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners17.00%

Commitments and Contingencies -

Commitments and Contingencies - Maturity analysis of operating leases payments (Details) - USD ($) $ in ThousandsMar. 31, 2021Dec. 31, 2020
Commitments and contingencies
2021 $ 242
2022192
Total434
Discount factor(29)
Lease liability405
Amount due within 12 months(297) $ (287)
Lease liability - long term $ 108 $ 186

Commitments and Contingencies_2

Commitments and Contingencies - Additional Information (Details) - USD ($)Jan. 01, 2019Mar. 31, 2021Mar. 31, 2020
Operating Lease, Weighted Average Discount Rate, Percent9.90%
Operating Lease, Cost $ 51,000 $ 50,000
Operating Lease, Payments79,000 $ 77,000
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability $ 0
Operating Lease Expiration Year2022
ASU 2016-02
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability $ 538,000